EUCTR2013-003387-32-GB进行中（未招募）不适用
Phase II Study Of The Impact Of AZD4017, A Selective 11b-HSD1 Inhibitor, On Biochemical Markers Of Bone Turnover In Post-Menopausal Osteopaenia - The impact of AZD4017 on bone turnover in post-menopausal osteopaenia
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Provision of informed consent prior to any study specific procedures.
- •2.Aged >50 and post-menopausal based on amenorrhoea for >12 months.
- •3.Documented presence of osteopaenia (bone density T-score at lumbar spine or hip of less than -1 and greater than -2.5 by Dual-energy X-ray Absorptiometry (DXA) criteria).
- •4.Placebo treatment for the duration of the study must not be considered detrimental to the study subject.
- •5.Must be able to understand the patient information sheet and consent form and comply with study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Bone Related Exclusion Criteria:
- •1Clinical or biochemical evidence of secondary causes of bone loss
- •2.25-OH vitamin D level <20nmol/L
- •3.The current or recent use (within 2 years) of medication likely to have an impact on bone (oestrogens, aromatase inhibitors, bisphosphonates, fluoride, denosumab, strontium ranelate, anti-convulsants, teriparatide; and oral, inhaled or nasal glucocorticoids). Patients already on calcium/vitamin D supplementation will continue this for the study. Those with a 25-OH vitamin D level of 20-50nmol/L at screening will be supplemented prior to inclusion.
- •General Exclusion Criteria:
- •1.Women of child-bearing potential.
- •2.eGFR calculated by MDRD equation <60ml/min/1.73m2.
- •3.Any endocrine disorder, eg, thyroid dysfunction.
- •4.Suspicion of or known Gilbert's disease.
- •5.CK >twice upper limit normal on 2 consecutive measurements.
- •6.Liver transaminases > upper limit normal.
- •7.Alkaline phosphatase > upper limit normal.
- •8.Bilirubin (total) > upper limit normal.
- •9.User of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
- •10.Uncontrolled systemic hypertension (BP >150/90); on 3 successive measurements on the morning of the screening visit.
- •11.Systemic (including vaginal/rectal) or inhaled glucocorticoid treatment at the time of the screening visit.
- •12.Probenicid therapy at the time of the screening visit.
- •13.Any screening laboratory abnormality that, in the investigator’s judgement, is considered to be clinically significant
- •14.History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject’s ability to participate in the study. Specifically, a diagnosis of any inflammatory disorder that might reasonably need treatment with glucocorticoids during the course of the study.
- •15.History of any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- •16.Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP as judged by the investigator.
- •17.Hypersensitivity or intolerance to 11ß-HSD1 antagonists or to AZD4017.
- •18.Involvement in the planning and/or conduct of the study
- •19.Participation in any other clinical study within 1 month prior to the screening visit.
- •20.Previous randomisation for treatment in the present study.
研究者
相似试验
已完成
2 期
STAG: effect of the drug AZD4017 on bone density in post-menopausal womePostmenopausal osteoporosisMusculoskeletal DiseasesOsteoporosisISRCTN32813419niversity of Leeds55
终止
1 期
Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female VolunteersHealthy VolunteersNCT00736788AstraZeneca16
未知
1 期
A Phase 1b, Dose Finding Study Evaluating AZD1775 in Monotherapy and in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Advanced Solid TumoursJPRN-jRCT2080222908AstraZeneca
已完成
1 期
Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral DosesDiabetes Mellitus Type 2NCT00841048AstraZeneca107
已完成
1 期
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.HealthyNCT00799747AstraZeneca56